Source: BioCentury

Mythic Therapeutics: Mythic: Enhancing ADC payload delivery using pH engineering

OCT 02, 2024 | 5:44 PM PDT | BIOCENTURY | EMERGING COMPANY PROFILEMYTHIC: ENHANCING ADC PAYLOAD DELIVERY USING PH ENGINEERINGBY Biotech engineers its antibody-drug conjugates to unbind their target upon internalization, recycling it back to the cell surface to recruit more ADCshttps://www.biocentury.com/article/653689/mythic-enhancing-adc-payload-delivery-using-ph-engineering© 2024 BioCentury Inc. All Rights Reserved

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
George Eliades's photo - President & CEO of Mythic Therapeutics

President & CEO

George Eliades

CEO Approval Rating

82/100

Read more